Colorado biotech reports drug test results; shares nosedive

A Westminster biopharmaceutical announced the results of a test of its drug treatment for atrial fibrillation and its shares were plummeting early Monday. Arca Biopharma Inc. (Nasdaq: ABIO) released the results of a test of its Gencaro treatment for cardiovascular disease. In early Monday trading, its shares were down more than 58 percent, falling 94 cents to 66 cents. The drug test involved 267 patients who were given either an active control, met oprolol succinate (Toprol-XL) or Gencaro. "In…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news